B-Cells and BAFF in Primary Antiphospholipid Syndrome, Targets for Therapy?

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder marked by blood clots, pregnancy issues, and antiphospholipid antibodies (aPL).
• Current treatments primarily focus on anticoagulation, but emerging evidence highlights the immune system's role in PAPS.
• The specific contribution of B-cells to PAPS pathophysiology remains largely unclear, despite their known involvement in other autoimmune diseases like systemic lupus erythematosus (SLE).

Purpose of the Study:

• To investigate the role of B-cells in the pathophysiology of primary antiphospholipid syndrome (PAPS).
• To explore the relationship between B-cell subsets, BAFF levels, and clinical manifestations in PAPS patients.
• To understand how B-cell-targeted therapies impact PAPS beyond autoantibody production.

Main Methods:

• Observational study analyzing B-cell subsets and BAFF levels in PAPS patients.
• Review of existing literature on B-cell involvement in autoimmune diseases.
• Analysis of treatment outcomes for PAPS patients receiving B-cell-depleting therapies like rituximab and belimumab.

Main Results:

• PAPS patients exhibit altered B-cell subsets, including increased plasmablasts.
• Elevated levels of B-cell activating factor (BAFF) are observed in PAPS patients.
• Treatments targeting B-cells (rituximab, belimumab) may improve clinical symptoms but do not decrease aPL levels.

Conclusions:

• B-cells play a significant role in PAPS pathophysiology, independent of autoantibody production.
• Altered B-cell dynamics and elevated BAFF suggest a complex immune contribution to PAPS.
• Further research is needed to elucidate the non-autoantibody-mediated functions of B-cells in PAPS.